Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 1998

View Archived Issues

Penederm: Q4 and FY 1997 highlights

Company Profile: Flamel Technologies

Magic bullet for cancer treatment finally found?

Schering-Plough discloses HCV NS3 protease inhibitors

K+ channel blockers patented by HMR for ulcers, arrhythmias

Estrogen replacement also a possibility in men?

Controlled-release melatonin for treating sleep disorders in the elderly

Several related series of MMP inhibitors claimed by Bayer

MENT: summary of concept data and preclinical and clinical results

Sustiva-containing combinations highly effective in reducing viral load in HIV-infected patients

Pernasal testosterone: a novel administration route for androgenic substitution

Eisai pursues a novel treatment strategy for allergy

Protein Sciences develops emergency vaccine against Hong Kong influenza

NeuroSearch signs agreement with Shire for CNS compounds

Antiviral/antiinflammatory combinations explored for HSV

EMEA decision on Zacutex MAA deferred

Atlantic's 2-5A antisense compound targets telomerase

Psovascar enters phase I/II for psoriasis

Lovenox approved for at-home use in U.S.

Glaxo Wellcome to acquire Polfa Poznan

Maxamine/Infergen combination to be tested in clinic

Captopril demonstrates antioxidant activity in new in vitro assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...